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Abstract ǀ Genome-wide molecular profiling studies have revealed characteristic genetic 
alterations and epigenetic profiles associated with different types of gliomas. These 
molecular characteristics can be used to refine glioma classification, to improve prediction of 
patient outcomes, and to guide individualized treatment. Thus, the WHO Classification of 
Tumours of the Central Nervous System was revised in 2016 to incorporate molecular 
biomarkers — together with classic histological features — in an integrated diagnosis, in 
order to define distinct glioma entities as precisely as possible. This paradigm shift is 
markedly changing glioma diagnostics, and has important implications for future clinical trials 
and patient management in daily practice. Herein, we highlight the developments in our 
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understanding of the molecular genetics of gliomas, and review the current landscape of 
clinically relevant molecular biomarkers for use in classification of gliomas. Novel approaches 
to the genetic characterization of gliomas based on large-scale DNA-methylation profiling 
and next-generation sequencing are also discussed. In addition, we illustrate how advances 
in the molecular genetics of gliomas can promote the development and clinical translation of 
novel pathogenesis-based therapeutic approaches, thereby paving the way towards 
precision medicine in neuro-oncology. 
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Malignant tumours of the central nervous system (CNS) are among the cancers with the 
poorest prognosis, as indicated by the association of brain tumours with the highest 
estimated number of years (mean: ~20 years) of potential life lost owing to any cancer1. 
Gliomas are the most common primary CNS tumours, with an estimated annual incidence of 
6.6 per 100,000 individuals in the USA2. About half of all newly diagnosed gliomas 
correspond to glioblastoma, which is the most malignant type of brain cancer — with median 
patient survival durations of approximately 14–17 months in contemporary clinical trials3-5 and 
~12 months in population-based studies2,6. 
 Studies in transgenic mice indicate that gliomas can arise from a range of cell types, 
including neural stem cells, astrocytes, or oligodendroglial progenitor cells7. Genome-wide 
molecular-profiling studies have revealed comprehensive mutational landscapes for all major 
types of human gliomas occurring in adults8-12 and children13-21. These developments have 
markedly advanced our mechanistic understanding of glioma tumorigenesis, and have 
identified novel biomarkers for improved tumour classification, as well as promising new 
therapeutic targets.  
 Before publication of the revised WHO Classification of Tumours of the CNS in 201622, 
gliomas were exclusively classified using light microscopy according to histological criteria 
defined in the 2007 WHO Classification23. In addition to histological tumour typing, each 
tumour is assigned to a histological grade based on the degree of anaplasia, from WHO 
grade I to IV. This WHO grading system reflects tumour malignancy and presumed natural 
disease course, with WHO grade I indicating a slow-growing lesion usually associated with 
favourable prognosis, whereas WHO grade IV is assigned to highly malignant tumours. 
Histological classification has for many decades served as the ‘gold-standard’ for glioma 
diagnostics, but is associated with considerable interobserver variability, particularly in the 
context of diffusely infiltrating gliomas24. Studies have revealed that molecular classifications 
of gliomas correlate better with clinical outcome than histological classification10,11,25,26. 
Moreover, certain histological entities, such as glioblastoma, encompass a spectrum of 
biologically distinct tumour groups associated with differences in age at onset, tumour 
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location, and prognosis8,9,12,21. In addition, some traditional glioma categories, including 
oligoastrocytoma and gliomatosis cerebri, lack disease-specific genetic profiles, and consist 
of diverse astrocytic and oligodendroglial entities27,28. In the revised 2016 WHO Classification 
of Tumours of the CNS22, the advances in our molecular understanding of gliomas are 
leveraged in a novel, multilayered approach to disease categorization incorporating both 
histological and molecular information in an ‘integrated diagnosis’ (BOX 1).29-30  
 In this Review, we highlight advances in the molecular genetics of gliomas, with a 
particular focus on diagnostically relevant alterations. In addition, we address the role of 
predictive biomarkers and novel high-throughput molecular testing in glioma diagnostics, and 
discuss the implications of these advances on the clinical management of patients with 
glioma, as well as the design of future clinical trials.  
 
[H1] Molecular genetics of adult gliomas  
A major improvement in the 2016 WHO classification of gliomas, compared with the 
preceding 2007 classification, is the distinction of different glioma entities according to 
isocitrate dehydrogenase 1 or 2 (IDH) mutation status (TABLE 1). The discovery of IDH 
mutations in most WHO grade II and III gliomas constituted a key breakthrough in 
understanding the disease31-33. Numerous studies have revealed that the presence of IDH 
mutations distinguishes gliomas with distinct biologies and clinical behaviours34. 
Mechanistically, mutant IDH proteins acquire a neomorphic enzymatic activity that results in 
conversion of α-ketoglutarate (α-KG) to D-2-hydroxyglutarate (D-2-HG), which in turn inhibits 
α-KG-dependent dioxygenases, such as ten-eleven translocation (TET) family 
5-methylcytosine hydroxylases and the Jumonji-C-domain-containing histone lysine 
demethylases35. Thereby, IDH mutation causes aberrant DNA and histone methylation, 
eventually leading to widespread hypermethylation of CpG islands, a phenomenon termed 
the ‘glioma CpG-island methylator phenotype’ (G-CIMP)36. Diagnostic testing for IDH 
mutations usually involves immunostaining with an antibody to IDH1 R132H protein37, which 
detects the most common missense mutation in gliomas present in approximately 90% of the 
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cases and has proved reliable across different laboratories38; however, immunonegative 
tumours require additional molecular testing — for example, by DNA sequencing — to rule 
out the presence of other IDH1 or IDH2 mutations22,30. In the following sections, we briefly 
summarize the genetic alterations most commonly associated with the prototypic glioma 
entities defined in the 2016 WHO classification (TABLE 1).  
 
[H2] Diffuse astrocytic and oligodendroglial tumours  
The diffuse astrocytic and oligodendroglial tumour category of brain cancers comprises 
diverse glioma subtypes. The main disease entities included in this group are IDH-mutant 
astrocytic gliomas of WHO grades II–IV, IDH-mutant and 1p/19q-codeleted oligodendroglial 
tumours of WHO grades II–III, IDH-wild-type glioblastomas of WHO grade IV, and a newly 
introduced class of histone H3 K27M (H3-K27M)-mutant diffuse midline gliomas of WHO 
grade IV (TABLE 2; FIG. 1)22. IDH-wild-type diffuse and anaplastic astrocytomas (WHO 
grades II and III, respectively) are provisional categories in the 2016 WHO classification 
(TABLE 2); in adults, most of these tumours are associated with a poor prognosis and often 
harbour genetic aberrations that are detected in IDH-wild-type glioblastomas, indicating that 
such cases might reflect underestimation of malignancy grade based on histology25,39. 
Importantly, however, a subset of IDH-wild-type diffuse astrocytomas share molecular 
similarities with pilocytic astrocytoma and are associated with favourable survival12. Thus, in 
patients with disease initially classified as IDH-wild-type diffuse or anaplastic astrocytoma, 
additional molecular testing for genetic aberrations associated with either IDH-wild-type 
glioblastoma, (for example, TERT-promoter mutations, EGFR amplification, loss of 
chromosome 10 and gain of chromosome 7), or pilocytic astrocytoma (such as KIAA11549–
BRAF fusion; TABLE 2) may provide diagnostically helpful information40. 
 
[H3] IDH-mutant astrocytic gliomas. IDH mutation is probably among the earliest genetic 
aberrations that occur during the development of these tumours11; however, findings in mice 
indicate that IDH mutation alone is not sufficient for tumorigenesis41. Indeed, IDH-mutant 
astrocytomas commonly carry additional mutations in TP53 and ATRX10,11, indicating that 
 - 6 - 
IDH-mutant astrocytoma development requires multiple genetic ‘hits’. ATRX mutations lead 
to immunohistochemically detectable loss of nuclear expression of the transcriptional 
regulator ATRX that is important in chromatin remodeling and regulation of telomere length42 
(FIG. 2a). Genetic alterations associated with progression from diffuse (WHO grade II) to 
anaplastic (WHO grade III) astrocytoma and eventually IDH-mutant (secondary) glioblastoma 
are variable and include chromosomal 9p21 deletions involving CDKN2A (encoding both 
cyclin-dependent kinase inhibitor 2A, also known as p16INK4A, and ARF, also known as 
p14ARF) and CDKN2B (encoding cyclin-dependent kinase 4 inhibitor B, also known as 
p15INK4B), deletion of 19q, and a variety of other chromosomal imbalances40. In addition, 
activation of MYC and the receptor tyrosine kinase (RTK)/RAS/PI3K pathway, upregulation 
of forkhead box protein M1 (FOXM1) expression and E2F2-dependent cell-cycle 
progression, and epigenetic silencing of developmental transcription factor genes regulated 
by the polycomb repressive complex 2 have been implicated in progression of IDH-mutant 
gliomas43. Accumulation of somatic mutations in inhibitors of the G1/S cell-cycle checkpoint, 
including members of the retinoblastoma (RB) pathway, and low levels of methylation at CpG 
sites in regulatory regions of genes involved in cell-cycle progression, e.g. TP73, further 
implicate dysregulated cell division as a convergence point of molecular events driving 
progression12,44. 
 
[H3] IDH-mutant and 1p/19q-codeleted oligodendroglial tumours. Oligodendrogliomas 
are genetically defined by coexistent IDH mutation and whole-arm codeletion of 
chromosome 1p and 19q (FIG. 2b) — the latter aberration is caused by an unbalanced 
t(1;19)(q10;p10) translocation45-46. Activating mutations in the TERT promoter (which lead to 
aberrant expression of telomerase reverse transcriptase)47 are present in >95% of 
oligodendroglial tumours and CIC mutation (resulting in inactivation of the protein homologue 
of Drosophila capicua, a transcriptional repressor) is detectable in more than two thirds of the 
cases48. Mutations in FUBP1 (encoding far upstream element-binding protein 1, which is 
involved in regulating MYC expression) are found in approximately one third of 
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oligodendroglial tumours (TABLE 2)48. Less common alterations affect developmental 
pathway genes, predominantly NOTCH1; genes encoding epigenetic regulators, such as 
SETD2; and PI3K pathway genes, for example, PIK3CA10,11. Genetic alterations that have 
been linked to a more-aggressive disease phenotype include 9p21 deletion49, mutations in 
the transcription factor 12 gene (TCF12)50, and aberrations resulting in activation of MYC 
signalling51. 
 
[H3] Oligoastrocytic gliomas. In the 2016 WHO classification, oligoastrocytomas are no 
longer considered as separate entities because they lack a distinctive genetic profile, and 
instead have either astrocytic or oligodendroglial genotypes10,11,27. Thus, testing for IDH 
mutation and 1p/19q codeletion is required22. Classification as oligoastrocytoma (or 
anaplastic oligoastrocytoma), not otherwise specified (NOS) is restricted to rare instances in 
which molecular testing remains inconclusive or could not be properly performed (TABLE 
2)22. Individual cases of IDH-mutant ‘oligoastrocytoma’ consisting of spatially and genetically 
distinct populations of oligodendroglial cells with 1p/19q codeletion and astrocytic cells 
without 1p/19q codeletion but loss of nuclear ATRX expression have been reported52 but are 
not recognized as separate disease entity in the WHO classification22. 
 
[H3] IDH-wild-type glioblastoma. IDH-wild-type glioblastomas WHO grade IV can arise in 
individuals of any age, but preferentially manifest in patients >50 years of age. These 
tumours typically manifest as ‘primary glioblastomas’ — that is, glioblastomas that present 
with a short clinical history of usually less than 3 months before diagnosis and without a pre-
existing lower-grade glioma22. Glioblastomas that develop de novo in non-midline locations in 
patients ≥55 years of age can be diagnosed as IDH-wild-type glioblastoma when 
immunohistochemical staining for IDH1 R132H is negative22. In patients aged <55 years and 
in patients with clinical evidence of pre-existing lower-grade glioma, exclusion of other IDH 
mutations is required — for example, via DNA sequencing — to fully rule out IDH-mutant 
glioblastoma (see below)22. IDH-wild-type glioblastomas in adults are characterized by 
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frequent gain of chromosome 7, monosomy of chromosome 10, mutation or homozygous 
deletion of PTEN, homozygous deletion of CDKN2A and CDKN2B, and TERT-promoter 
mutations (TABLE 1)53; other less-common alterations include mutations in TP53, PIK3CA, 
PIK3R1 (encoding PI3K-regulatory subunit 1), and NF1 (encoding neurofibromatosis type 
1)9. Gene amplifications are commonly detected in IDH-wild-type glioblastomas, and involve 
the EGFR, PDGFRA, and MET genes encoding mitogenic RTKs; the cyclin-dependent 
kinases genes CDK4 and CDK6 that mediate transition from G1 to S phase of the cell cycle; 
and MDM2 and MDM4, which encode proteins that inhibit the activity of p53 (TABLE 1)53. 
EGFR amplification is detectable in about 40% of IDH-wild-type glioblastomas, with half of 
these tumours also harbouring a genetic rearrangement that results in deletion of EGFR 
exons 2–7 34,53. This aberration leads to expression of EGFR variant III (EGFRvIII; FIG. 2c), 
which lacks the extracellular ligand-binding region encoded by the deleted exons, but is 
constitutively active53. BRAFV600E is a rare, but druggable mutation in IDH-wild-type 
glioblastoma that is detectable in approximately 50% of epithelioid glioblastomas (FIG. 2d)54, 
a newly described provisional variant of IDH-wild-type glioblastoma. Other histological 
variants are giant cell glioblastoma and gliosarcoma (TABLE 2)22.  
  
[H3] IDH-mutant glioblastoma. The IDH-mutant glioblastoma subtype accounts for <10% of 
all glioblastomas and typically manifest in young adults22. These tumours include almost all 
secondary glioblastomas that develop via progression from pre-existing lower-grade gliomas. 
Consequently, the molecular profile associated with this class of gliomas is similar to that of 
IDH-mutant astrocytomas, including frequent TP53 and ATRX mutation alongside a G-CIMP 
phenotype53. Lower DNA-methylation levels as usually present in IDH-mutant and G-CIMP-
positive astrocytic gliomas have been detected in a subset of patients and are associated 
with less favourable outcome12. However, the prognosis of patients with IDH-mutant 
glioblastoma is typically better — with a greater likelihood of long-term survival — than that of 
patients with IDH-wild-type glioblastoma due to younger mean age at diagnosis, higher 
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frequency of MGMT-promoter methylation (see below) and other, yet to be identified 
factors34,53.  
 
[H3] Molecular subgroups of adult glioblastoma. mRNA-expression analyses have 
revealed four distinct subtypes of glioblastoma: proneural, neural, classic and 
mesenchymal55. The clinical utility of stratifying patients according to these expression 
signatures is limited, however, as they can be heterogeneous within a given tumour and can 
change in response to external stimuli, including therapy56,57. Nevertheless, the 
mesenchymal expression signature has been linked to radioresistance and poor survival54, 
whereas the proneural signature has been associated with a benefit from antiangiogenic 
treatment in patients with IDH-wild-type glioblastoma.58  
 DNA-methylation profiles can be used to robustly distinguish glioblastoma subgroups 
associated with specific epigenetic patterns and gene-expression profiles8,9. Four major 
subgroups of adult glioblastoma have been identified, including an IDH-mutant, G-CIMP-
positive and typically MGMT-promoter-methylated subgroup with proneural gene-expression 
profile, and three subgroups of IDH-wild-type glioblastoma (FIG. 3). Among the IDH-wild-type 
glioblastoma subgroups, ‘receptor tyrosine kinase I’ (RTK I) glioblastomas predominantly 
occur in adolescents and young adults, and are characterized by PDGFRA amplification and 
a proneural gene-expression profile. The ‘receptor tyrosine kinase II’ (RTK II) and the 
‘mesenchymal’ IDH-wild-type glioblastoma subtypes predominate in patients older than 50 
years of age, and are distinguished by different DNA-methylation profiles, with fewer copy 
number variations and a mesenchymal versus classic gene-expression signature in 
mesenchymal glioblastoma (FIG. 3)8. 
 
[H1] Molecular genetics of paediatric gliomas  
Paediatric gliomas comprise three major disease groups: firstly, tumours with circumscribed 
growth that often harbour BRAF aberrations; second, tumours with diffuse growth and 
frequent alterations in FGFR1 or rearrangement of MYB, or the MYBL genes; third, a 
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heterogeneous group of malignant gliomas, including tumours with mutations in histone-H3-
family genes.  
 
[H2] Gliomas with circumscribed growth 
[H3] Pilocytic astrocytoma. The most common form of glioma with circumscribed growth, 
pilocytic astrocytoma (WHO grade I), is characterized by genetic alterations that result in 
activation of MAPK signalling (TABLE 1)15; fusion of the BRAF and KIAA1549 genes on 
chromosome 7q is common, particularly in cerebellar tumours (FIG. 2e), and has been 
associated with favourable patient outcome59. Subsets of pilocytic astrocytomas carry fusions 
involving different MAPK-pathway genes, such as RAF1, PTPN11, or NTRK2, or harbour 
mutations in BRAF, KRAS, FGFR1, or NF115. Mutations in non-MAPK-pathway genes are 
usually absent, making pilocytic astrocytoma a ‘single-pathway disease’15. Pilomyxoid 
astrocytoma is a rare, histological variant of pilocytic astrocytoma associated with a higher 
likelihood of local recurrence and cerebrospinal spread (TABLE 2)22.  
  
[H3] Pleomorphic xanthoastrocytoma. Pleomorphic xanthoastrocytoma (PXA) is typically 
associated with BRAFV600E mutation, often occurring together with homozygous deletion of 
CDKN2A and loss of p16INK4A expression (TABLE 2)60-62. Genetic alterations that drive 
progression of WHO grade II PXA towards WHO grade III anaplastic PXA are poorly defined, 
as is the relationship between anaplastic PXA and epithelioid glioblastoma, which also 
harbour BRAFV600E mutations63. 
  
[H3] Subependymal giant-cell astrocytoma. The development of subependymal giant-cell 
astrocytoma (WHO grade I) is closely linked to aberrations affecting the tuberous sclerosis 
complex (TSC). The typical genetic changes are mutation and allelic losses leading to loss of 
either hamartin (TSC1) or tuberin (TSC2) expression (TABLE 1), which results in activation 
of the mTOR-signalling pathway64. 
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[H2] Well-differentiated diffuse gliomas  
Unlike their adult counterparts, diffuse gliomas in children usually lack IDH mutation and 
1p/19q codeletion16,65. Subsets of paediatric diffuse gliomas harbour FGFR1 alterations, 
rearrangements of MYB or the MYBL genes, or BRAF aberrations (TABLE 1)16,66. However, 
these tumour groups are not yet considered as distinct entities or variants in the 2016 WHO 
classification22. They typically portend a favourable prognosis and malignant progression is 
uncommon. Angiocentric glioma, a rare WHO grade I glioma with infiltrative growth in 
children and young adults, is characterized by MYB–QKI fusion rearrangements that may 
promote tumorigenesis via three different mechanisms: MYB activation by truncation, 
enhancer translocation driving aberrant MYB-QKI expression, and hemizygous loss of the 
tumor suppressor QKI 67.  
 
[H2] Malignant gliomas and glioblastomas 
H3-K27M mutant diffuse midline glioma is a WHO grade IV glioma typically located in the 
thalamus, brain stem or spinal cord22. This disease entity includes more than 70% of diffuse 
intrinsic pontine gliomas (DIPGs) in children14. The genetic hallmark of these tumour types, 
K27M mutation in the histone H3-encoding genes H3F3A or HIST1H3B/C13,14, leads to global 
reduction of cellular histone H3 lysine 27 (H3-K27) trimethylation (FIG. 2f) via impaired 
recruitment of the polycomb repressive complex 2 and inhibition of the histone-lysine N-
methyltransferase EZH268,69. Of note, findings from preclinical studies with GSK-J4, which 
inhibits lysine-specific demethylase 6B (a Jumonji-C-domain-containing histone-lysine 
demethylase), and panobinostat, a pan-histone-deacetylase inhibitor, suggest a potential for 
epigenetic therapy in the treatment of H3-K27M-mutant gliomas70,71.  
H3-K27M-mutant gliomas frequently harbour mutations in TP53 and/or PPM1D (encoding 
magnesium-dependent protein phosphatase 1D); amplification of proto-oncogenes, such as 
PDGFRA, MYC, MYCN, CDK4, CDK6, or CCND1-3 (encoding cyclin D1–3), ID2, and MET is 
also common13,14,18 (TABLE 1; FIG. 3). About 20% of DIPGs carry activin receptor 1 gene 
(ACVR1) mutations, whereas FGFR1 alterations are mostly associated with thalamic 
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tumours14,18. H3F3AK27M-mutant DIPGs differ from their HIST1H3BK27M-mutant counterparts 
by a proneural versus a mesenchymal gene-expression profile, and the former have been 
associated with a less-favourable outcome72. 
 Hemispheric malignant gliomas in children comprise different molecular subgroups, 
including H3F3AG34-mutant tumours and a small fraction (~6% of paediatric glioblastomas in 
one series)21 of IDH-mutant glioblastomas (FIG. 3). IDH-wild-type glioblastomas with genetic 
profiles similar to those of IDH-wild-type glioblastomas in adults also occur in children, and 
are associated with poor prognosis21; however, approximately 20% of paediatric 
glioblastomas have prognostically favourable epigenetic profiles related to PXA or well-
differentiated (low-grade) paediatric gliomas21.  
 
[H1] Molecular genetics of ependymal tumours  
A study published in 2015 revealed nine distinct biological subgroups of ependymomas, 
consisting of three subgroups each among spinal, posterior fossa, and supratentorial 
tumours20. Prognostically favourable tumours with subependymoma-like molecular profiles 
can occur at each of these anatomical sites.  
More than two thirds of supratentorial ependymomas in children carry gene 
rearrangements that result in fusion proteins involving the NF-κB subunit RELA and 
C11orf95 (TABLE 1)19,20. These RELA-fusion-positive tumours, which have an aberrant NF-
κB transcriptional programme and an unfavourable prognosis, constitute a novel entity in the 
2016 WHO classification (TABLE 2)22. Less commonly, supratentorial ependymomas 
harbour YES-associated protein 1 (YAP1) fusions (TABLE 1), and these tumours are 
associated with more-favourable outcomes20.  
Among posterior fossa ependymomas, a prognostically unfavourable subgroup (PF-A), is 
characterized by genomic stability, and tumours in this subgroup are probably mainly driven 
by epigenetic mechanisms as recurrent genetic alterations have not been identified 
(TABLE 1)20. Another subgroup (PF-B) has chromosomal instability, but a clinically less-
aggressive phenotype20,73.  
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Spinal ependymomas are mostly indolent tumours, with intramedullary ependymomas 
frequently demonstrating NF2 mutations (TABLE 1), while myxopapillary ependymomas of 
the filum terminale often show multiple numerical chromosome aberrations20. Among all 
ependymoma subgroups, RELA-fusion-positive supratentorial ependymomas and PF-A 
ependymomas are associated with the worst outcomes as indicated by a 10-year overall 
survival rate of approximately 50% compared to 88-100% in the other subgroups in a large 
restrospective cohort20.  
  
[H1] Glioma biomarkers 
[H2] Entity-defining molecular biomarkers  
The 2016 WHO classification of gliomas incorporates IDH mutation, 1p/19q codeletion, 
H3-K27M mutation and C11orf95–RELA fusion as diagnostic biomarkers that define distinct 
glioma entities (TABLE 2). Other biomarkers can provide additional diagnostic information, 
including loss of nuclear ATRX expression, TERT-promoter mutation, BRAF mutation or 
fusion, and H3-G34 mutation30,40. If molecular testing cannot be performed, or the results 
remain inconclusive, the term ‘NOS’ (not otherwise specified) has been introduced to indicate 
that the diagnosis is based on histology only — that is, information on the relevant 
biomarker(s) was not available for an integrated diagnosis (TABLE 1)22,30. 
 
[H2] Predictive molecular biomarkers 
The number of biomarkers of predictive significance for guiding the post-surgery treatment of 
patients with glioma is increasing74. Among these, the presence of MGMT-promoter 
methylation is predictive of benefit from alkylating agent chemotherapy in patients with 
IDH-wild-type glioma, particularly in elderly patients75,76. Long-term follow-up studies of two 
phase III trials in patients with anaplastic glioma have revealed that 1p/19q codeletion is a 
predictive marker for benefit from upfront combined radiotherapy and chemotherapy with 
procarbazine, lomustine, and vincristine (PCV)77,78. Other genetic aberrations are emerging 
as potential predictive biomarkers of response to glioma therapy40 (TABLE 3). 
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[H3] MGMT-promoter methylation. The standard drug used in concomitant 
radiochemotherapy and maintenance chemotherapy for glioblastoma is the DNA-alkylating 
agent temozolomide79. A major temozolomide-induced DNA-adduct, 6-O-methylguanine, is 
effectively repaired by 6-O-methylguanine-DNA methyltransferase (MGMT; also known as 
methylated-DNA--protein-cysteine methyltransferase), via alkylation of the enzyme itself, 
followed by ubiquitylation and subsequent proteasomal degradation of the enzyme80. Thus, 
MGMT expression levels correspond to the cellular 6-O-methylguanine-repair capacity, and 
tumour cells with low or absent MGMT expression are rendered more sensitive to 
temozolomide80. Approximately 40% of IDH-wild-type glioblastomas demonstrate 
hypermethylation of a MGMT-associated 5'-CpG island, which results in transcriptional 
repression and reduced MGMT expression80. This epigenetic change is known as MGMT-
promoter methylation, and has been closely linked to benefit from temozolomide therapy and 
prolonged survival of patients with glioblastoma3,81. Moreover, phase III trials in glioblastoma 
patients aged >65 years revealed that MGMT-promoter methylation is a highly relevant 
biomarker for guiding treatment decisions between radiotherapy or temozolomide 
chemotherapy75,76. The predictive role of MGMT-promoter methylation for response to 
temozolomide might be restricted to IDH-wild-type gliomas, however. MGMT-promoter 
methylation is present in most IDH-mutant and G-CIMP-positive gliomas and portends a 
favourable prognosis in these settings, but is not linked to differential benefit from either 
temozolomide or radiotherapy82. 
 MGMT-promoter methylation usually occurs homogeneously within different regions of an 
individual glioma83, and remains stable over the course of disease84. Nevertheless, tumours 
with MGMT-promoter methylation can acquire secondary temozolomide resistance owing to 
mutations that drive clonal evolution and tumour recurrence. For example, mutations in DNA 
mismatch repair genes can cause a hypermutator genotype85. Despite the clinical 
significance of MGMT-promoter methylation, diagnostic testing remains challenging owing to 
heterogeneous methylation of MGMT-associated CpG sites between different tumours, 
unclear thresholds for defining ‘positivity’ in tumours with weakly or borderline detectable 
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MGMT-promoter methylation, and the use of diverse, nonstandardized testing methods40,80. 
Thus, harmonization of test protocols, and establishment of internal and external quality 
assessments are important to assure robust diagnostic results. 
 
[H3] 1p and 19q codeletion. 1p/19q codeletion has been implicated as independent 
predictive biomarker of benefit from the addition of PCV chemotherapy to upfront treatment 
with irradiation in patients with anaplastic glioma77,78. The mechanisms underlying the 
favourable treatment responses and long-term survival of patients with IDH-mutant and 
1p/19q-codeleted gliomas (median overall survival of >10 years) are poorly understood. Of 
note, only whole-arm 1p/19q codeletion combined with IDH mutation is prognostically 
favourable; partial deletions on either chromosome arm, which can occur in IDH-wild-type 
glioblastomas, are associated with poor patient outcomes86. 
 
[H3] Emerging predictive biomarkers. BRAFV600E mutation has emerged as a promising 
predictive biomarker of response to BRAF inhibitors in patients with glioma.87 Similarly, 
detection of IDH mutation is important to identify patients suitable for evaluation of treatments 
with inhibitors of mutant IDH88, or peptide-based vaccination targeting IDH1 R132H89 in 
clinical trials. Likewise, treatments targeted at EGFR or EGFRvIII would require predictive 
testing for EGFR amplification or EGFRvIII positivity90-94. Another potential predictive 
biomarker is the presence of FGFR–TACC fusions, which may identify patients with 
glioblastoma who are potentially eligible for FGFR-inhibitor therapy95,96.  
 
[H2] Novel molecular diagnostics approaches  
Each of the biomarkers we have discussed can be assessed using tests predicated on a 
single protein or gene, involving immunohistochemistry, fluorescence in situ hybridisation 
(FISH), DNA sequencing, or other methods40. However, the advent of high-throughput 
technologies for molecular testing, including microarray-based procedures and next-
generation sequencing (NGS), provides promising opportunities for the development of novel 
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diagnostics (BOX 2). At present, application of whole-exome or whole-genome sequencing is 
mostly restricted to research projects and selected clinical trials, e.g. the INFORM trial in 
paediatric patients97 or the NCT Neuro Master Match (N2M2) and NCI-MATCH trials in adult 
patients98,99. However, NGS of brain-tumour-tailored gene panels is already performed in 
clinical practice in some centres, typically covering between ~20  to ~150 genes known to be 
mutated in gliomas and/or other types of brain tumours100-103. This technique can be applied 
to routinely processed tissue samples, and enables sequencing of diagnostically relevant 
genes, as well as identification of actionable mutations at high sensitivity and specificity. 
Thereby, fast and robust parallel analysis of multiple markers can be achieved at affordable 
costs. Another complementary approach involves DNA-methylation profiling using microarray 
technology, which has revealed distinct molecular subgroups among anaplastic gliomas25, 
glioblastomas8,21, and ependymal tumours20 as described in previous sections of this Review. 
Use of this approach has also revealed that gliomatosis cerebri is not a distinct entity28. 
Moreover, copy-number changes across all chromosomes and MGMT-promoter methylation 
status can be assessed in parallel with the DNA methylation profiles using special 
bioinformatics algorithms for analysis of the microarray data 25,104. The use of these and other 
advanced molecular assays will soon become a widespread practice.  
The current WHO classification of glioma relies exclusively on assessments of tumour 
tissue; however, ‘liquid biopsy’ approaches using ultra-deep sequencing of DNA from 
cerebrospinal fluid or plasma, for example, hold promise for non-invasive diagnostics and 
disease monitoring of various cancers, including gliomas105-107. Glioma-associated micro-
RNAs, such as miR-21, can also be detected in cerebrospinal fluid, and may potentially 
serve as diagnostic, prognostic, and/or predictive biomarkers108,109.  
 
[H1] Current multimodal therapy of gliomas  
 
Despite tremendous advances in understanding glioma genetics, molecularly targeted 
therapies have, to date, failed in phase III trials in patients with this disease, and the classic 
treatment modalities of surgery, radiotherapy and/or chemotherapy remain the mainstay of 
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therapy34,74. Surgery can be curative in patients with circumscribed gliomas, such as pilocytic 
astrocytoma, PXA, and subependymal giant-cell astrocytoma (FIG. 4). Most ependymomas 
also have circumscribed growth, but local brain invasion is common and the risk of 
dissemination within the CNS increases with the duration of the disease; therefore, complete 
resection is prognostically favourable, but consolidating radiotherapy is often required for 
prolonged tumour control in patients with anaplastic ependymoma and following incomplete 
resection of WHO grade II ependymoma110. 
 Gross total resection is also associated with improved survival of patients with diffuse 
gliomas, including glioblastoma111,112, not excluding the growing group of elderly 
patients75,113. Diffuse gliomas generally recur after resection; therefore, additional treatment 
aimed at prolonging survival while maintaining quality of life is the standard of care. The 
choice and timing of the various available treatments depend on patient age, clinical 
performance status, tumour entity, and molecular biomarkers (FIG. 4). Postsurgical 
radiotherapy provides improved local control in patients with diffuse gliomas of any grade 
when compared with surgery alone. Furthermore, radiotherapy prolongs survival in patients 
with WHO grade III and IV gliomas and is therefore standard of care.74 Delaying radiotherapy 
until recurrence progression after surgery does not compromise the overall survival in 
patients with WHO grade II gliomas114, but such ‘watchful waiting’ strategies should only be 
considered for patients aged <40 years and with favourable prognostic factors115,116 (FIG. 4). 
The RTOG 9802 trial117 results demonstrated that patients with WHO grade II diffuse gliomas 
considered to require treatment beyond surgery experienced prolonged survival when PCV 
polychemotherapy was added to radiotherapy. In contrast, the EORTC 22033-26033 trial that 
compared radiotherapy alone with chemotherapy alone did not result in the identification of 
any subgroup of patients with a clear benefit from either treatment over the other118. 
 1p/19q codeletion is a predictive biomarker of long-term benefit from PCV 
polychemotherapy administered immediately before or after radiotherapy in patients with 
anaplastic glioma77,78 (FIG. 4a). Whether the PCV regimen can be substituted by 
temozolomide will be explored in the new CODEL trial119. Whether the benefit from adding 
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PCV to radiotherapy observed in a subset of patients with tumours lacking 1p/19q codeletion 
is linked more closely to IDH mutation120 or MGMT-promoter methylation121 remains 
controversial. Nevertheless, preliminary data from the CATNON trial122 have confirmed a role 
of early maintenance alkylating chemotherapy with temozolomide after radiotherapy in 
patients with anaplastic glioma lacking 1p/19q codeletion. 
 The standard of care for patients with glioblastoma is postoperative chemoradiotherapy, 
with 60 Gy in 30 fractions and concomitant daily temozolomide, followed by six cycles of 
maintenance temozolomide (TMZ/RT→TMZ; FIG. 4b)74,79. This treatment approach was 
established based on the results of a trial that did not include patients aged >70 years79, and 
subgroup analyses have suggested only limited benefit from addition of temozolomide to 
radiotherapy in patients aged 65–70 years123. Trials in elderly glioblastoma patients (variably 
defined as patients aged ≥60-70 years of age), who have a particularly poor prognosis, 
demonstrated the efficacy of shorter, hypofractionated radiotherapy regimens in this 
population123,124, and a predictive role of MGMT-promoter methylation for benefit from first-
line temozolomide alone75,76. Nonetheless, elderly patients with MGMT-promoter-methylated 
tumours who are eligible for combined modality treatment can benefit from the 
TMZ/RT→TMZ regimen125. 
 The definition of standards of care at glioma recurrence remains challenging. Gross total 
resection is associated with prolonged survival in patients with recurrent glioblastoma126, but 
the value of repeat surgery is less clear in patients with other gliomas. Surgery merely to 
reduce tumour volume — rather than with the aim of achieving gross tumour resection — is 
under debate because the validity of the retrospective studies suggesting beneficial effects, 
compared with no repeat surgery, is challenged by major imbalances in prognostic factors 
between the treatment cohorts74. Radiotherapy at recurrence is an option for patients who 
did not receive first-line radiotherapy, but is limited by neurotoxic dose-accumulation effects 
that may cause radionecrosis127. Systemic treatments that can be used at disease 
recurrence include alkylating agent chemotherapy, mostly with lomustine and/or CCNU128,129, 
or re-challenge with temozolomide in patients with MGMT-promoter methylation and 
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apparent benefit from first-line treatment with this agent130,131; however, effects on survival 
are moderate at best. In the USA and some other countries, antiangiogenic therapy with 
bevacizumab was approved for the treatment of recurrent glioblastoma on the basis of 
radiographic response rates in the range of 20-40% — and presumed clinical benefit — in 
two uncontrolled trials132,133; approval was conditional on the subsequent demonstration of an 
overall survival benefit, which was achieved neither in studies in patients with newly 
diagnosed glioblastomas4,5, nor when bevacizumab was combined with CCNU in the 
treatment of patients with recurrent disease134. Application of ‘tumour treating fields’ (TTF), 
that is, alternating electric fields that are applied via skin electrodes placed on the shaved 
scalp, prolonged the survival of patients with newly diagnosed glioblastoma in a phase III 
trial135; however, skepticism surrounds this approach, owing to trial design issues, the 
uniformity of results across subgroups, and a small effect magnitude relative to the 
potentially major adverse effects on quality of life136. 
  
[H1] Mechanisms of progression after therapy  
Gliomas are characterized by intratumoural heterogeneity of cells with distinct profiles of 
molecular aberrations, which might facilitate malignant progression and therapy resistance. 
IDH mutations are generally retained in recurrent tumours43,137, thus underscoring the role of 
these alterations as tumour-initiating events (that is, ‘driver’ mutations) and a potential 
therapeutic target. The IDH mutation-associated G-CIMP is usually also maintained at 
disease recurrence44; however, malignant progression can be accompanied by a reduction in 
the frequency of methylated CpG sites, and rare tumours show loss of G-CIMP at 
recurrence, which has been associated with poor outcomes12. 
 By contrast, increased DNA methylation upon glioma progression has been observed at a 
small fraction of CpG sites, particularly those in genes encoding developmental transcription 
factor families with key roles in pattern formation and cell-fate determination. Notably, 
patterns of hypermethylated CpGs required for maintenance of the human embryonal stem-
cell (hESC) phenotype are enriched upon progression towards glioblastoma, including the 
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promoters of genes that are strongly silenced in hESC as a result of H3-K27 trimethylation43. 
Thus, a high grade of histological malignancy is associated with stem-like features, a finding 
that supports the hypothesis that stem-like cells mediate resistance to chemotherapy and/or 
radiotherapy as derived mostly from studies of IDH-wild-type glioblastomas138-140. The lack of 
a defining molecular marker profile challenges the prospective identification and in situ 
characterization of such stem-like cells. Instead, models of glioma stem-like cells rely on 
enrichment strategies based on single or multiple marker-based segregation using e.g. 
CD15, CD44, or CD133141. Marker-positive cells are then propagated in the brains of 
immune-compromised mice or in vitro under stem-cell versus non-stem-cell promoting 
growth conditions to retrospectively confirm enrichment of stem-like traits; however, selection 
and epigenetic biases must be considered when interpreting data from these models56. 
Genetic differences between glioma stem-like and non-stem-like cells have not been defined, 
although an epigenetic pattern resembling that of paediatric glioblastomas with H3F3A 
mutation is characteristic of CD133-positive stem cells142. Single-cell mRNA-expression 
studies have revealed a dynamic distribution of stem-like versus more-differentiated traits, 
contributing to glioblastoma intratumour heterogeneity57. Depletion of glioma stem-like cells, 
via targeted disruption of CD44 or the nuclear receptor tailless (Tlx), improved survival in 
preclinical models143,144; however, early clinical trials evaluating therapies targeting glioma 
stem-like cells, e.g., utilizing the sonic hedgehog signaling inhibitor GDC0449 (vismodegib) 
or the notch signaling inhibitor RO4929097, failed to induce durable tumor responses145,146.  
 Clonal selection during malignant progression can favour cells that lack mutations present 
in the initially predominant clones (including oncogenic drivers, such as TP53, ATRX, 
FUBP1, SMARCA4 and BRAF)43,137, indicating that alternative pathways of progression can 
diverge at early stages of tumour evolution, even without the selective pressure inferred by 
anticancer treatments. Temozolomide chemotherapy can, however, contribute to malignant 
progression by inducting a hypermutation state that is associated with driver mutations in 
components of the RB1 and mTOR pathways137. Defects in genes encoding DNA mismatch 
repair proteins are thought to underlie the hypermutation state, and could potentially be used 
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to identify patients at risk of therapy-associated malignant progression147. Indeed, the 
MGMT-promoter methylation status is essentially unaffected by progression of glioblastomas 
after treatment with the TMZ/RT→TMZ regimen82, thus implicating alternative mechanisms of 
temozolomide-resistance including DNA mismatch repair deficiency leading to DNA 
hypermutation84,85,137.  
 Resistance of diffuse gliomas to radiotherapy can be mediated by activation of the 
DNA-damage response139,148, and a rapid radiotherapy-induced switch towards a 
mesenchymal gene-expression pattern that results in enhanced pro-survival signalling via 
NF-κB to counteract proapoptotic signals56,149. Formation of an interconnecting microtubule 
network between glioma cells has been proposed as a new mechanism of radioresistance150. 
Ultimately large sets of well-annotated, matched samples from individual patients collected 
before and after therapy will be required to characterize the molecular basis of glioma 
chemotherapy and radiotherapy resistance.  
 
[H1] Novel pathogenesis-based treatments  
[H2] Targeting oncogenic signalling pathways  
Improved understanding of the molecular mechanisms that underlie gliomagenesis has 
prompted attempts to target identified drivers of the disease. Such approaches are 
particularly promising in circumscribed gliomas that are driven by activation of a single 
pathway. For example, treatment with the mTOR-inhibitor everolimus is efficacious in 
patients with subependymal giant-cell astrocytomas, in terms of reductions in tumour 
volumes and seizure frequencies151,152, and responses to the BRAF inhibitor vemurafenib 
have been reported in patients with BRAFV600E-positive recurrent PXA153,154. A clinical trial of 
vemurafenib is ongoing in paediatric patients with BRAFV600E-positive recurrent malignant 
gliomas155. A recent phase 1/2 trial of the mutant BRAF inhibitor dabrafenib in pediatric 
patients with BRAFV600–mutant relapsed or refractory low-grade gliomas revealed promising 
activity as indicated by an objective response rate of 41%156. By contrast, preclinical studies 
in KIAA1549–BRAF-fusion-positive pilocytic astrocytomas revealed that PLX4720, an 
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analogue of vemurafenib, induced paradoxical activation of MAPK signalling157. Similarly, 
sorafenib treatment resulted in paradoxical MAPK-pathway activation and accelerated 
tumour growth in patients with pilocytic astrocytoma158. Use of the MAPK-pathway inhibitor 
selumetinib might circumvent this limitation, and this agent is currently under clinical 
investigation for treatment of patients with pilocytic astrocytomas159. The more-diverse 
biology of ependymomas suggests that similarly straight-forward treatment approaches might 
not be effective in this disease, but trials of everolimus, or hormone-receptor blockade in 
HER2-positive ependymoma, are ongoing34. 
 In glioblastoma, complete response of a paediatric patient with BRAFV600E-positive 
glioblastoma to vemurafenib provides further proof of principle for targeting aberrant 
signalling pathways160. Other examples include the association of benefit from therapy using 
the mTOR inhibitor temsirolimus with phosphorylation of the downstream mTOR target 
ribosomal protein S6 kinase β1 (S6K1) detected in tumour samples from patients with 
recurrent glioblastoma161, and with mTOR S2448 phosphorylation detected in tumour 
specimens from those with newly diagnosed MGMT-unmethylated glioblastoma (in post-hoc 
analyses)162. Efficacy studies using these molecular entry criteria are, however, not 
underway. Overall, the targeted inhibition of oncogenic signalling has not proven effective in 
randomized controlled trials involving patients with glioblastoma 129,162,163,164 Several early 
trials were performed to evaluate the efficacy of EGFR inhibitors in patients with diffuse 
gliomas, but none monitored for the presence of EGFR amplification in tumour cells as a 
potential predictive biomarker of response165. A recent promising approach exploits EGFR 
amplification to deliver the microtubule toxin monomethyl auristatin F through a drug-
conjugated antibody directed specifically to the activated conformation of EGFR166.  
Resistance to oncogenic signalling inhibitors is related to clonal diversity, which can be 
bypassed by targeting aberrations that occurred early in tumourigenesis and thus are shared 
by all (or almost all) tumour cells. IDH mutation is a key example of this type of oncogenic 
aberration. Indeed, preclinical data indicate that small-molecule inhibitors of mutant IDH 
proteins can reverse the G-CIMP signature, induce glial differentiation, and inhibit the growth 
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of IDH-mutant glioma cells88. Early stage clinical trials of such agents are ongoing in 
advanced IDH-mutant malignancies, including gliomas167-169. The concept of epigenomic 
reshaping utilizing inhibitors of H3-K27 demethylase and histone deacetylases has also been 
explored with promising results in preclinical models of H3-K27M-mutant paediatric brain 
stem gliomas70,71. In IDH-wild-type glioblastomas, EGFRvIII has been identified as a driver of 
epigenetic remodelling that promotes tumour growth170, but EGFRvIII is expressed in only 
subsets of tumour cells and is relatively resistant to inhibitors of EGFR signalling171, thus 
presenting challenges for therapeutic targeting of this aberration. 
 The extensive vascularity of glioblastoma has prompted investigations of several 
antiangiogenic approaches to therapy, including the use of small-molecule inhibitors of VEGF 
signalling, the anti-VEGF antibody bevacizumab, and inhibition of integrins by a cyclic 
peptide (cilengitide); however, enthusiasm for such strategies has been dampened by 
reports of several negative phase III trials4,5,134,164. Nevertheless, subgroup analyses of 
AVAGlio4, a placebo-controlled phase III trial designed to assess the addition of 
bevacizumab to standard first-line chemoradiotherapy in patients with newly diagnosed 
glioblastoma, indicate that a proneural gene-expression signature might be a biomarker for 
benefit from antiangiogenic therapy58. 
 In spite of the potential to identify disease drivers and the available means to target these 
aberrations in diffuse gliomas, mosaicism of genomic alterations172, clonal selection, and 
treatment-induced evolution, as well as dose-limiting toxicities, and other pharmacokinetic 
and pharmacodynamic issues complicate clinical translation of molecularly targeted 
treatments173. Combinations of the different treatment approaches individualized according to 
molecular features and the clonal composition of each tumour, and possibly involving 
sequential biopsies, might be required to overcome spatial and temporal heterogeneity of 
diffuse gliomas. 
 
[H2] Immunotherapy approaches 
Gliomas are not considered highly immunogenic because, in contrast to tumours against 
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which immunotherapy has proven effectiveness (such as melanoma or non-small-cell lung 
cancer), mutational loads are typically low. Moreover, gliomas are characterized by profound 
immunosuppression mediated by secreted (TGF-β, IL-10) and cell surface (CD95L, PD-L1) 
immunosuppressive factors, by infiltration of immune inhibitory cells in the tumor 
microenvironment and by anatomical peculiarities of the brain such as the blood brain barrier 
and paucity of lymphatic vessels174,175. Nevertheless, multiple strategies to overcome this 
immunosuppression and exploit antitumour immune responses have been pursued in 
patients with gliomas. Firstly, vaccination, that is, immunization with tumour-specific or 
tumour-associated peptides, or by application of autologous antigen-presenting cells boosted 
with such peptides. Secondly, immunomodulatory drugs that target T-cell inhibitory signalling 
to enhance physiological antitumour responses. Finally, adoptive T-cell transfer, which 
involves in vitro clonal expansion or genetic engineering of T-cells with high avidity for 
tumour-specific or tumour-associated epitopes176. 
 
[H3] Vaccination. EGFRvIII has been considered a promising target yielding tumour-specific 
epitopes for boosting antitumour adaptive immune responses with minimal risk of cross-
reactivity against nontumour cells. In combination with bevacizumab therapy, vaccination 
with an EGFRvIII-specific peptide, rindopepimut (also known as CDX-110), seemed to 
prolong survival of patients with EGFRvIII-positive recurrent glioblastoma in an exploratory 
randomized phase II trial94. In patients with newly diagnosed EGFRvIII-positive glioblastoma, 
however, overall survival was unaffected by addition of rindopepimut to standard 
temozolomide maintenance therapy in the double-blind, placebo-controlled, phase III ACT-IV 
trial177. Despite this setback, EGFRvIII remains an attractive treatment target in patients with 
glioblastoma and continues to be explored in this context. R132H-mutant IDH is another 
potential target for single-peptide vaccination approaches. Epitopes containing the mutated 
portion of this protein are presented on MHC class II molecules and induce mutation-specific 
CD4+ T-cell responses, anti-IDH1-R132H CD4+ T cells and antibodies occur spontaneously 
in patients with IDH1R132H-mutant glioma. and this vaccination approach evoked durable 
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anticancer responses in a preclinical glioma model89.  
 The transfer of autologous dendritic cells (DCs) pulsed ex vivo with tumour-associated 
peptides (or RNAs encoding such peptides) is currently being explored as an alternative 
vaccination strategy. For example, in 12 patients with glioblastoma, immunization with DCs 
pulsed with the cytomegalovirus (CMV) antigen pp65 RNA, which is expressed in >90% of 
glioblastomas, but not in surrounding nonmalignant brain tissue, triggered antitumour T-cell 
responses that were reinforced by preconditioning of the vaccine site with the recall antigen 
tetanus/diphtheria toxoid178. Moreover, prolongation of progression-free survival by 2.4 
months was reported in a placebo-controlled phase II trial exploring addition of the DC 
vaccine ICT-107 to maintenance therapy for patients with newly diagnosed glioblastoma179. 
ICT-107 comprises autologous DCs pulsed with six synthetic peptides from glioma-
associated antigens MAGE-1, HER-2, AIM-2, TRP-2, gp100, and IL-13Rα2; in this trial 
unpulsed DCs were used as the placebo179. A pivotal phase III trial has been launched to 
further evaluate this approach180. The use of a DC vaccine in addition to standard therapy for 
patients with newly diagnosed glioblastoma has also been explored in the phase III DCVax 
trial181, wherein autologous DCs were pulsed with tumour lysates derived from the same 
patient; however, results of this trial have not been released yet.  
 
[H3] Immune-checkpoint blockade. The immunosuppressive microenvironment of gliomas 
is a major caveat that can limit the effectiveness of immunotherapy182. Monoclonal antibodies 
directed at the inhibitory immune checkpoints mediated by the T-cell receptors cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4; ipilimumab) or programmed cell-death protein 1 
(PD-1; nivolumab and pembrolizumab) have entered clinical practice, notably as treatments 
of metastatic melanoma and non-small-cell lung cancers183-186. Furthermore, antibodies to 
PD-1 ligand 1 (PD-L1) are being developed — and one such agent, atezolizumab, has been 
approved by the FDA for the treatment of bladder cancer. In addition, antibodies neutralizing 
other immunoreceptors, such as killer-cell immunoglobulin-like receptors (KIR) or lymphocyte 
activation gene 3 (LAG-3) have been developed182. Interestingly, immune-checkpoint 
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blockade resulted in tumour eradication in an immunocompetent glioblastoma model187, and 
impressive clinical responses to nivolumab have been observed in two siblings with recurrent 
multifocal, DNA-mismatch-repair-deficient glioblastoma188. Current trials being conducted to 
evaluate immunomodulatory drugs in glioma include the phase III CheckMate-143 trial of 
nivolumab and bevacizumab in patients with recurrent glioblastoma189, the double-blind 
phase II CheckMate-548 trial of nivolumab therapy as an adjunct to standard 
chemoradiotherapy in patients with newly diagnosed MGMT-methylated glioblastoma190, and 
the open-label phase III CheckMate-498 trial assessing the efficacy of nivolumab as an 
alternative to temozolomide in patients with newly diagnosed MGMT-unmethylated 
glioblastoma191.  
  
[H3] CAR T-cell therapy. Another immunotherapeutic concept involves adoptive transfer of 
genetically engineered chimeric antigen receptor (CAR) T cells, which have been modified to 
express binding domains with high affinity for tumour antigens linked to intracellular signalling 
domains that trigger T-cell activation, proliferation, and persistence, similar to normal T-cell 
receptors192. Severe ‘on-tumour’ toxicity, attributable to cytokine release by activated 
CAR T cells, has been associated with this therapeutic approach, for example, in patients 
with haematological malignancies193; however, ‘on-target, off-tumour’ cross-reactivity can 
also result in severe organ-specific toxicity, such as neurological toxicity owing to targeting of 
neurons expressing melanoma-associated antigen A (MAGE-A) proteins by autologous 
anti-MAGE-A3 CAR T cells194. Nevertheless, this treatment paradigm holds promise for 
glioma therapy. For instance, treatment with CAR T cells directed at EGFRvIII195 or 
podoplanin196 reduced glioma growth in mouse models. Early clinical trials using CAR T-cells 
targeting EGFRvIII197 or HER2198 are ongoing in patients with glioblastoma. HER2 expression 
on cardiomyocytes warrants close monitoring of cardiac function in patients who receive 
HER2-targeting CAR T cells; however, cardiac failure was not observed in 19 patients with 
sarcoma treated with such cells199. 
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[H1] Innovative clinical trial design  
The low incidence rates of various gliomas challenge patient accrual to sufficiently powered 
clinical trials. Generally, the number of events and thus statistical power of oncology trials 
can be increased by creating national and international networks to maximize patient 
recruitment, by minimizing trial durations, by inclusion of composite or continuous outcome 
measures, such as quality-of-life outcomes, and by minimizing ‘noise’ by ensuring high-data 
quality200. Historical controls have also been used to reduce sample size in past single-arm 
phase II trials in patients with glioma, but a series of phase III trials with a rationale built on 
such trials had negative results128,129,164, thus raising questions regarding this approach. Of 
note, the overall survival of patients with glioblastoma treated in the standard 
chemoradiotherapy control arms of clinical trials has improved substantially during the past 
decade, ranging from 14.6 months in the pivotal EORTC/NCIC trial79 to approximately 17 
months in contemporary phase III trials3-5,135, probably owing to improved surgical technique, 
more-aggressive treatment of recurrent disease, and better management of treatment-
related complications. Importantly, these improvements in care can distort the outcome 
measures of single-arm trials in which the survival of contemporary cohorts is compared to 
that of historical cohorts201. 
 Molecular stratification of gliomas augments the challenge of patient accrual, but might 
increase the yield of a study by accurately selecting the ‘right’ patients for treatment with the 
‘right’ molecularly targeted therapies. A constant increase in knowledge of the molecular 
mechanisms that drive gliomagenesis and the failure of previous trials of molecular targeted 
therapies for gliomas underscore the need for a step back towards hypothesis-generating 
phase II trial designs, because only combination treatments that counter anticipated escape 
mechanisms will ultimately overcome treatment resistance. Two-step designs, such as 
adaptive and crossover trials including repeat biopsy sampling to enable the use of molecular 
diagnostics, have been advocated for this purpose in the setting of other rare cancers200; 
however, such designs might be difficult to apply in glioma trials owing to the costs and risks 
associated with cranial surgery, and because clinical deterioration at tumour progression can 
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preclude further trial participation in a substantial proportion of patients. Nevertheless, 
comparison of molecular tumour profiles before and after therapy, as well as examination of 
tissue from ‘responders’ versus ‘non-responders’ are important in generating hypotheses for 
combination treatments to overcome resistance, and might yield novel biomarkers for 
prediction of escape mechanisms in individual patients.  
 Classical one-fits-all trial designs whereby randomization is based on histology alone are 
outdated (FIG. 5a), and biomarker-based entry criteria are increasingly applied. Different 
treatment options can then be randomly allocated to the biomarker-positive versus the 
biomarker-negative patients, in order to maximize recruitment (FIG. 5b). In trials involving 
patients with diffuse glioma, IDH mutation, 1p/19q codeletion and MGMT-promoter 
methylation are commonly determined at diagnosis and are candidates for biomarker-based 
stratification. Several ongoing trials are incorporating more-specific molecular entry criteria. 
For example, assessment of EGFR amplification is being performed in the clinical 
development programme of the anti-EGFR antibody–drug conjugate ABT-414202,203 and in an 
uncontrolled trial of the small-molecule EGFR-inhibitor dacomitinib204 which is anticipated to 
cross the blood–brain barrier more readily than previously evaluated EGFR inhibitors.92,93. 
Moreover, assessment of rare fusion proteins and activating mutations involving the FGFR 
gene95,96 is being incorporated in a trial of a novel FGFR-inhibitor (BGJ398)205. Basket trials 
extend biomarker-based patient recruitment according to the rationale that a particular 
molecular alteration validates a clinical target for which a specific inhibitor is available, 
independent of disease site or histology. By contrast, umbrella trials offer the opportunity for 
maximizing recruitment by enabling patient stratification using multiple molecular markers, for 
example, particular genetic alterations detected in subsets of patients with the same cancer 
type that can be targeted with different inhibitors (FIG. 5c). In basket and umbrella trials, the 
intent is not to compare the outcomes of patients in the different treatment arms. Instead, 
these designs can be viewed as incorporating several separate phase II trials — enabling 
investigation of the efficacy of either a single agent in the different diseases included in the 
‘basket’ of a common molecular target, or multiple different therapies allocated based on 
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molecular profiles under the ‘umbrella’ of a common disease. Randomization of patients with 
rare cancers to a control arm is not feasible and, therefore, response assessment is the 
primary outcome measure used in these trials. The key strength of basket and umbrella trials 
is the prospective annotation of clinical and molecular data to generate hypotheses for 
testing in future randomized trials; thus, repeated biopsy sampling at disease progression 
should be included in such designs.  
 Tremendous technological progress in microarray-based and NGS-based diagnostics 
poses novel opportunities for such innovative trial approaches, although molecular 
stratification based on high-throughput technologies is challenged by logistical issues, such 
as availability of sufficient amounts of tissue, insufficient depths of sequencing to detect 
clones of low abundance, consumption of time and resources, and a limited consensus on 
data interpretation206. Moreover, basket and umbrella trials require a functional molecular 
screening platform and potentially the involvement of multiple pharmaceutical companies in 
order to obtaining a reasonable assortment of drugs with which to target the detected 
molecular aberrations, but are, nevertheless, the most-promising approach to developing a 
precision-medicine strategy for patients with glioma. Ongoing or upcoming prospective 
studies using NGS-based diagnostics include the INFORM registry basket trial in paediatric 
patients with recurrent cancers including gliomas97, the NCT Neuro Master Match (N2M2) 
umbrella trial in patients newly diagnosed MGMT-promoter-unmethylated glioblastoma98, and 




Advances in molecular profiling technologies have enabled the characterization of genetic 
and epigenetic changes in gliomas at a hitherto unprecedented comprehensiveness. New 
biomarkers have been identified that can improve diagnostic accuracy and guide 
individualized treatment. These developments have led to the 2016 update of the WHO 
Classification of Tumours of the CNS that breaks with the traditional approach of purely 
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histology-based glioma diagnostics by incorporating molecular biomarkers in an integrated 
diagnosis. In parallel, improved knowledge of glioma biology has provided opportunities for 
novel pathogenesis-based pharmacological treatments and innovative immunotherapeutic 
strategies; for example, new strategies for targeting tumour-associated mutant proteins or 
immune checkpoints have emerged. Moreover, innovative trial concepts have been initiated 
that involve predictive molecular profiling followed by individualized therapy specifically 
tailored to the characteristics of each tumour. Thus, the time has come for expand the 
implementation of precision medicine in neuro-oncology.  
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Key points  
 
The 2016 WHO Classification of Tumours of the Central Nervous System represents a 
paradigm shift, replacing traditional histology-based glioma diagnostics with an integrated 
histological and molecular classification system that enables more-precise tumour 
categorization  
 
o The requisite diagnostic biomarkers for the 2016 WHO classification of gliomas are 
IDH1/2 mutations, 1p/19q codeletion, H3F3A or HIST1H3B/C K27M (H3-K27M)  
mutations and C11orf95–RELA fusions  
 
o Additional diagnostically relevant biomarkers include loss of nuclear ATRX expression, 
TERT-promoter mutations, KIAA1549–BRAF fusion, BRAFV600E mutation, H3-G34 
mutation, and several other alterations associated with rare glioma entities 
 
o MGMT-promoter methylation is predictive of benefit from alkylating chemotherapy,  
particularly in elderly patients with IDH-wild-type glioblastoma; predictive biomarkers for 
targeted therapies, such as IDH1 and BRAF mutations, are also emerging 
 
o Novel methods for large-scale DNA-methylation, copy-number and mutational profiling 
will further advance the assessment of glioma-associated molecular biomarkers 
 
o Clinical trials require assessment of molecular biomarkers as criteria for study entry 
and/or patient stratification; predictive DNA sequencing followed by targeted therapy will 
support the implementation of precision medicine in neuro-oncology  
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BOX 1 | The integrated diagnosis concept used in the 2016 WHO 
Classification of Tumours of the Central Nervous System (CNS)  
 
The 2016 WHO Classification of Tumours of the CNS22 follows a multilayered approach 
for glioma classification, combining three layers of information derived from the tumour to 
determine the final (‘top layer’) integrated diagnosis, as follows:  
 
 Top layer:  Final (integrated) diagnosis incorporating all tissue-based information 
 Layer 3: Molecular information (results of molecular testing for diagnostic biomarkers) 
 Layer 2: Histological tumour grade (WHO grade) 
 Layer 1: Histological tumour type 
For example, tumours of the histological ‘oligodendroglioma’ subtype (layer 1) and WHO grade II 
(layer 2) that harbour an IDH1 mutation and 1p/19q codeletion (layer 3) have a final (top layer) 
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BOX 2 | Novel high-throughput technologies for the molecular diagnosis of glioma 
 
Microarray-based DNA-methylation profiling  
Can provide information on diagnostic DNA-methylation profiles and DNA copy-number 
alterations (CNAs).  
• Advantages: applicable to formalin-fixed paraffin-embedded (FFPE) material; no 
blood-cell-derived DNA required as a reference; and is relatively inexpensive 
• Limitations: cannot detect subtle alterations, such as point mutations  
 
Sequencing of glioma-associated gene panels 
Provides information on mutations and CNAs of selected cancer-related genes.  
• Advantages: applicable to FFPE material; small gene panels might not require 
analysis of blood-cell-derived DNA as a reference; enables high sequence coverage 
from very low amounts of DNA; and is relatively inexpensive 
• Limitations: cannot detect DNA-methylation changes, such as MGMT-promoter 
methylation 
 
Diagnostic whole-exome or whole-genome sequencing  
Provides information on mutational profiles across all coding exons or the entire genome of a 
given tumour. 
• Advantages: provides a comprehensive overview of mutations, CNAs and complex 
chromosomal rearrangements 
• Limitations: requires blood-cell-derived DNA for reference; requires bioinformatics 
expertise; relatively expensive; and cannot detect DNA-methylation changes, such as 
MGMT-promoter methylation   
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Figure 1 ǀ Diagnostic approach for integrated histological–molecular classification of 
diffuse gliomas according to the 2016 WHO Classification of Tumours of the Central 
Nervous System22. In addition to histological typing and grading, diffuse gliomas are 
evaluated for IDH1/IDH2 (IDH) mutation status. Nuclear ATRX expression is determined by 
immunohistochemistry. Testing for 1p/19q codeletion is performed in patients with IDH-
mutant tumours with retained nuclear ATRX expression to further refine the classification of 
these tumours. IDH-wild-type gliomas located in midline structures (thalamus, brain stem, or 
spinal cord) are additionally tested for H3-K27M mutation. Dashed lines indicate small 
subgroups of tumours with the respective diagnoses. *Nuclear ATRX expression retained in 
most IDH-wild-type WHO grade II/III astrocytic tumours. ‡IDH-wild-type WHO grade II/III 
astrocytoma is considered a provisional entity in the 2016 WHO Classification of Tumours of 
the Central Nervous System. 
 
Figure 2 ǀ Histological and molecular features of selected glioma entities. a ǀ This 
tumour was identified as an anaplastic astrocytic glioma on hematoxylin and eosin (HE) 
staining and had immunopositivity for IDH1 R132H and loss of nuclear ATRX expression on 
immunohistochemical (IHC) analysis, leading to a diagnosis of anaplastic astrocytoma, IDH-
mutant (WHO grade III). b ǀ HE staining revealed a cellular glioma composed of tumour cells 
with round nuclei and a clear cytoplasm; DNA pyrosequencing revealed an IDH2R172K 
mutation (c.515G>A, shown is the sequence of the reverse strand) and microsatellite 
analysis demonstrated loss of heterozygosity at the D1S468 (1p) and D19S219 (19q) loci —
 arrows indicate alleles lost in tumour DNA (T) relative to blood DNA (B). These features 
enabled a diagnosis of anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted 
(WHO grade III). c ǀ These photomicrographs indicate features of glioblastoma, IDH wild type 
(WHO grade IV). Note microvascular proliferation visible on HE staining (arrow), the lack of 
IDH1 R132H immunostaining and expression of EGFR variant III (EGFRvIII) on IHC analysis. 
d ǀ HE staining revealed a cellular tumour composed of epithelioid cells, with focal glial 
fibrillary acidic protein (GFAP) expression detected on IHC analysis; DNA sequencing of the 
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tumour revealed a BRAFV600E mutation (c.T1799A, shown is the sequence of the reverse 
strand). These features enabled a diagnosis of glioblastoma, IDH-wild-type, epithelioid 
variant (WHO grade IV). e ǀ An example of a pilocytic astrocytoma (WHO grade I): a spindle-
cell astrocytoma with biphasic growth pattern on HE staining, immunopositivity for OLIG2, 
and expression of a KIAA1549–BRAF fusion transcript detected by reverse transcription-
PCR (row A: PCR products for KIAA1549 exon 15/BRAF exon 9 fusion transcripts; row B: 
PCR products for BRAF-wild-type transcripts; lane 1: PCR bands obtained for the depicted 
tumour sample revealing KIAA1549–BRAF positivity; lane 2: KIAA1549–BRAF-negative 
control; lane 3: KIAA1549–BRAF-positive control; lane 4: no template control). f ǀ 
Characteristics of a diffuse midline glioma, H3-K27M-mutant (WHO grade IV). Histological 
analyses revealed a diffuse astrocytic glioma (HE staining) with nuclear immunopositivity for 
K27M-mutated histone H3 (H3-K27M), and loss of nuclear positivity on IHC staining for 
trimethylated lysine 27 of histone 3 (H3K27me3). Specific immunoreactivity in the IHC 
photomicrographs is indicated by 3,3-diaminobencidine staining (brown); IHC sections are 
counterstained with hemalum (light blue). 
 
Figure 3 ǀ Molecular subgroups of glioblastoma, as defined by distinct genetic and 
epigenetic profiles8,21,40. Among the glioblastoma subtypes predominantly found in children 
below 18 years of age, tumours with pleomorphic xanthoastrocytoma (PXA)-like or low-grade 
glioma (LGG)-like molecular profiles are associated with favourable outcomes, whereas 
prognosis for patients with H3-K27M-mutant diffuse midline gliomas is unfavourable. The H3-
G34-mutant subgroup most commonly develops in children and young adults before 30 
years of age. IDH-mutant glioblastomas most commonly manifest in young adults between 
20 and 50 years of age and hold the best prognosis of all the adult glioblastoma types. 
Receptor tyrosine kinase I (RTK I) tumours also tend to occur in young adults. RTK II 
(classic) and mesenchymal glioblastomas are the most-common glioblastoma types in 
patients older than 50 years of age and are associated with poor prognosis. Genes mutated 
in each subgroup are indicated, as is the approximate percentage of patients with MGMT-
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promoter-methylated tumours in each group. Chr., chromosome; G-CIMP, glioma-associated 
CpG-island methylator phenotype; OS, overall survival. *BRAFV600E mutation detectable in a 
minor fraction of tumours; ‡Corresponds to diffuse midline glioma, H3-K27M-mutant; 
§Mutated in a subset of diffuse intrinsic pontine gliomas; ǀǀMutated in a subset of H3-K27M-
mutant tumours; Modified with permission from Elsevier B.V.© Masui K., Mischel, P.S. & 
Reifenberger, G. Handb. Clin. Neurol. 134, 97–120 (2016). 
 
Figure 4 ǀ Current post-surgery treatment strategies for major glioma entities classified 
according to the 2016 WHO Classification of Tumours of the Central Nervous 
System22. a ǀ Standard post-surgery treatments of IDH-mutant adult gliomas. b ǀ Standard 
post-surgery treatments of IDH-wild-type adult gliomas. c ǀ  Standard post-surgery 
treatments of common paediatric glioma entities. Dashed lines indicate smaller subgroups of 
patients with the respective diagnoses. PCV, procarbazine, CCNU (lomustine), and 
vincristine; RT, radiotherapy; SEGA, subependymal giant-cell astrocytoma; TMZ, 
temozolomide; TMZ/RT → TMZ, radiotherapy with concomitant and maintainance 
temozolomide. * Diffuse astrocytoma, IDH-wild-type (WHO grade II) and anaplastic 
astrocytoma, IDH-wild-type (WHO grade III) are provisional entities according to the 2016 
WHO classification.  
 
 
Figure 5 ǀ Schematic illustration of different clinical trial designs. a ǀ Conventional 
clinical trials usually randomly allocate patients into an experimental (Exp) arm and a 
standard treatment arm for reference. b ǀ Trial design with stratification of patients into 
different treatment arms based on individual biomarkers and comparison to standard 
treatments. c ǀ Umbrella trial design to compare different types of targeted treatment for a 
particular cancer type based on molecular profiling of the tumour in each patient followed by 
allocation of individualized treatment; patients with tumours that lack actionable mutations 
are assigned to the standard-of-care arm. 
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TABLE 1 ǀ Common genetic, epigenetic and chromosomal aberrations associated with 
the major glioma entities40  
Glioma entity  Genetic   Epigenetic   Chromosomal 
Diffuse astrocytic and oligodendroglial tumours 
Diffuse astrocytoma, IDH-mutant IDH1 or IDH2, TP53, ATRX mutation G-CIMP Trisomy 7 or 7q 
gain; LOH 17p 
Anaplastic astrocytoma, IDH-mutant IDH1 or IDH2, TP53, ATRX mutation G-CIMP Trisomy 7 or 7q 
gain; LOH 17p 
Oligodendroglioma, IDH-mutant and 
1p/19q-codeleted 
IDH1 or IDH2, TERT, CIC, FUBP1 
mutation 
G-CIMP 1p/19q codeletion  
Anaplastic oligodendroglioma, IDH-
mutant and 1p/19q-codeleted 
 IDH1 or IDH2, TERT, CIC, FUBP1, 
TCF12 mutation; CDKN2A deletion  
G-CIMP 1p/19q codeletion 
   
Glioblastoma, IDH-mutant IDH1 or IDH2, TP53, ATRX mutation; 
CDKN2A homozygous deletion 
G-CIMP Trisomy 7 or 7q 
gain; LOH 17p; 10q 
deletion    
Glioblastoma, IDH-wild-type* TERT, PTEN, TP53, PIK3CA, PIK3R1, 
NF1, H3F3AG34 mutation; CDKN2A, PTEN 
homozygous deletion; EGFR, PDGFRA, 
MET, CDK4, CDK6, MDM2 MDM4 
amplification; EGFRvIII rearrangement 
MGMT-promoter 
methylation 
Trisomy 7 or 7q 
gain; monosomy 10; 
double minute 
chromosomes  
Diffuse midline glioma, H3-K27M-
mutant‡ 
H3F3AK27M or HIST1H3B/CK27M, TP53, 
PPMD1, ACVR1, FGFR1 mutation, 
PDGFRA, MYC, MYCN, CDK4, CDK6, 
CCND1-3, ID2, MET amplification 
Loss of histone H3 
lysin trimethylation  
- 
Well-differentiated paediatric diffuse 
glioma§ 
MYB or MYBL rearrangement; FGFR1 
duplication 
- - 
Other (astrocytic) gliomas 
Pilocytic astrocytoma BRAF, RAF1, NTRK2 gene fusions; 
BRAFV600E, NF1, KRAS, FGFR1, PTPN11 
mutation 
- -   
Pleomorphic xanthoastrocytoma BRAFV600E mutation, CDKN2A/p14ARF 
homozygous deletion 
- - 
Subependymal giant cell 
astrocytoma 
TSC1 or TSC2 mutation and LOH - - 
Angiocentric glioma MYB–QKI gene fusions/rearrangements - - 
Supratentorial ependymal tumours 
Ependymoma, RELA-fusion 
positiveǀǀ 
C11orf95–RELA fusion - 11q aberrations  
Ependymomaǀǀ YAP1 gene fusions - 11q aberrations 
Posterior fossa (PF) ependymal tumours 
Ependymoma PF-Aǀǀ - PF-A DNA methylation 









Spinal intramedullary ependymal tumours  
Ependymoma NF2 mutation - 22q deletion,  
Modified with permission from Elsevier B.V.© Masui K., Mischel, P.S. & Reifenberger, G. Handb. Clin. Neurol. 134, 97–120 
(2016).*For further stratification into molecular subgroups, see FIG. 3. ‡Includes diffuse intrinsic pontine gliomas  §Group of 
IDH-wild-type diffuse gliomas in children that have not been recognized as a distinct WHO entity. ǀǀIncludes WHO grade II and III 
tumours. CIN, chromosomal instability; EGFRvIII, EGFR variant III; G-CIMP. glioma CpG-island methylator phenotype (includes 
frequent MGMT-promoter methylation); H3-K27M, K27M-mutated histone H3; LOH, loss of heterozygosity. 
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TABLE 2 ǀ 2016 WHO classification of gliomas22  
Tumour classification  WHO grade 
Diffuse astrocytic and oligodendroglial tumours  
Diffuse astrocytoma, IDH-mutant  
• Gemistocytic astrocytoma, IDH-mutant 
II 
II 
Diffuse astrocytoma, IDH-wild-type* II 
Diffuse astrocytoma, NOS II 
Anaplastic astrocytoma, IDH-mutant III 
Anaplastic astrocytoma, IDH-wild-type* III 
Anaplastic astrocytoma, NOS III 
Glioblastoma, IDH-wild-type 
• Giant-cell glioblastoma 
• Gliosarcoma 





Glioblastoma, IDH-mutant IV 
Glioblastoma, NOS IV 
Diffuse midline glioma, H3-K27M-mutant IV 
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted II 
Oligodendroglioma, NOS II 
Anaplastic oligodendroglioma, IDH mutant and 1p/19q-codeleted III 
Anaplastic oligodendroglioma, NOS III 
Oligoastrocytoma, NOS‡ II 
Anaplastic oligoastrocytoma, NOS‡ III 
Other astrocytic tumours  
Pilocytic astrocytoma 
• Pilomyxoid astrocytoma 
I  
-  
Subependymal giant cell astrocytoma I 
Pleomorphic xanthoastrocytoma II 
Anaplastic pleomorphic xanthoastrocytoma III 
Ependymal tumours  
Subependymoma I 
Myxopapillary ependymoma I 
Ependymoma 
• Clear cell ependymoma 
• Papillary ependymoma 





Ependymoma, RELA-fusion-positive II or III 
Anaplastic ependymoma III 
Other gliomas  
Chordoid glioma of the third ventricle II 
Angiocentric glioma I 
Astroblastoma  - 
NOS categories are reserved for the rare instancies that a tumour cannot be molecularly tested or that 
test results remain inconclusive22. H3-K27M, K27M-mutated histone H3; NOS, not otherwise specified. 
*Provisional tumour entities or variants. ‡The diagnosis of ‘oligoastrocytoma, NOS’ or ‘anaplastic 
oligoastrocytoma; NOS’ is discouraged in the 2016 WHO classification of gliomas22:  oligoastrocytic 
(mixed) gliomas should be assigned either to an astrocytic or an oligodendroglial tumour entity via 
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TABLE 3 ǀ Predictive molecular biomarkers relevant to gliomas 
Biomarker Application References 
Predictive biomarkers in clinical use 
MGMT promoter 
methylation 
Prediction of benefit from alkylating chemotherapy in patients with 
IDH-wild-type gliomas, in particular elderly patients with 
glioblastoma  
75,76 
1p/19q codeletion Prediction of benefit from upfront radiotherapy and PCV as 
opposed to radiotherapy alone in patients with anaplastic glioma  
77,78 
Examples of emerging novel predictive biomarkers 
BRAF mutation Identification of patients with BRAFV600-mutant gliomas eligible for 
BRAF-inhibitor therapy 
87,153–156,160 
IDH1/IDH2 mutation Identification of patients with IDH-mutant diffuse gliomas eligible 
for peptide-based vaccination or mutant-IDH inhibitors 
88,89 
EGFRvIII expression Identification of patients with EGFRvIII-positive glioblastomas 
eligible for EGFRvIII-peptide-based vaccination 
90,91,94 
EGFR amplification Identification of patients with EGFR-amplified glioblastomas 
eligible for treatment with anti-EGFR antibodies 
92,93 
FGFR–TACC fusion Identification of patients with FGFR–TACC-positive glioblastomas 
eligible for FGFR-inhibitor therapy 
95,96 
EGFRvIII, EGFR variant III; PCV, procarbazine, CCNU (lomustine), and vincristine. 
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